Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neratinib as adjuvant therapy in patients with HER2 positive breast cancer: expert opinion.
Caputo R, Buono G, Di Lauro V, Cianniello D, Von Arx C, Pensabene M, Pagliuca M, Pacilio C, Di Rella F, Verrazzo A, Martinelli C, Nuzzo F, De Laurentiis M. Caputo R, et al. Among authors: pensabene m. Future Oncol. 2023 Aug;19(24):1695-1708. doi: 10.2217/fon-2023-0361. Epub 2023 Aug 22. Future Oncol. 2023. PMID: 37605877 Review.
Combined effect of obesity and diabetes on early breast cancer outcome: a prospective observational study.
Buono G, Crispo A, Giuliano M, De Angelis C, Schettini F, Forestieri V, Lauria R, Pensabene M, De Laurentiis M, Augustin LSA, Amore A, D'Aiuto M, Tortoriello R, Accurso A, Cavalcanti E, Botti G, Montella M, De Placido S, Arpino G. Buono G, et al. Among authors: pensabene m. Oncotarget. 2017 Dec 5;8(70):115709-115717. doi: 10.18632/oncotarget.22977. eCollection 2017 Dec 29. Oncotarget. 2017. PMID: 29383194 Free PMC article.
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F; GIM Investigators. De Placido S, et al. Lancet Oncol. 2018 Apr;19(4):474-485. doi: 10.1016/S1470-2045(18)30116-5. Epub 2018 Feb 23. Lancet Oncol. 2018. PMID: 29482983 Clinical Trial.
Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.
Piezzo M, Chiodini P, Riemma M, Cocco S, Caputo R, Cianniello D, Di Gioia G, Di Lauro V, Rella FD, Fusco G, Iodice G, Nuzzo F, Pacilio C, Pensabene M, De Laurentiis M. Piezzo M, et al. Among authors: pensabene m. Int J Mol Sci. 2020 Sep 3;21(17):6400. doi: 10.3390/ijms21176400. Int J Mol Sci. 2020. PMID: 32899139 Free PMC article.
Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors.
Piezzo M, Cocco S, Caputo R, Cianniello D, Gioia GD, Lauro VD, Fusco G, Martinelli C, Nuzzo F, Pensabene M, De Laurentiis M. Piezzo M, et al. Among authors: pensabene m. Int J Mol Sci. 2020 Sep 4;21(18):6479. doi: 10.3390/ijms21186479. Int J Mol Sci. 2020. PMID: 32899866 Free PMC article. Review.
Tumor characteristics and prognosis in familial breast cancer.
Arpino G, Pensabene M, Condello C, Ruocco R, Cerillo I, Lauria R, Forestieri V, Giuliano M, De Angelis C, Montella M, Crispo A, De Placido S. Arpino G, et al. Among authors: pensabene m. BMC Cancer. 2016 Nov 29;16(1):924. doi: 10.1186/s12885-016-2962-1. BMC Cancer. 2016. PMID: 27899083 Free PMC article.
62 results